先声药业与Aeromics宣布合作,在大中华区共同研发和商业化脑水肿治疗药物AER-271

美国康涅狄格州纽黑文、中国南京,2019年11月5日 –  先声药业与Aeromics公司今日宣布,双方签署独家合作协议,将在大中华区(包括中国大陆、香港、澳门及台湾地区)共同研发和商业化脑水肿治疗药物AER-271。根据合作条款,先声药业将负责大中华区域内AER-271的临床开发和商业化。AER-271是临床阶段的抗脑水肿药物,开发用来治疗脑卒中和其他适应症。

Aeromics公司董事会执行副主席Thomas Zindrick表示:“我们很高兴与先声药业在中国合作开发AER-271。先声药业在中国脑卒中治疗领域一直处于领先地位,同时兼具卓越的研发能力和领先的开放合作队伍,使其成为Aeromics的理想合作伙伴。”

先声药业首席科学官王品博士表示:“脑水肿是颅脑损伤、脑血管疾病等多种常见神经系统疾病的严重并发症,有着巨大的未被满足的临床需求。Aeromics公司在该领域拥有卓越的研发团队和项目经验,先声药业在中枢神经系统药物的研发及市场推广方面也已有较深厚的积累,我们很高兴能与Aeromics深度合作,并非常期待在双方的共同努力下,让AER-271尽早惠及广大患者。”

Aeromics公司董事会成员、因发现水离子通道荣获2003年诺贝尔化学奖的Peter Agre博士表示:“通过Aeromics和先声药业在专业领域的相得益彰,我非常高兴双方将基于对水通道蛋白生物学的科学共识,共同推动针对重大未满足临床需求的治疗药物的开发。”

根据合作条款,Aeromics将获得首付和额外的里程碑付款(包括开发、监管、销售阶段),此外,根据净销售额提成从个位数到两位数不等。先声药业将负责AER-271在大中华区的开发和商业化,同时获得AER-271在全球其他区域净销售额的个位数提成。协议的具体财务条款尚未披露。

关于脑卒中

在中国,每隔20-30秒就会新增一名脑卒中患者。目前,中国每年大约有250万脑卒中患者,其中一大部分患者可能遭受危及生命的严重致残性脑水肿或脑肿胀。水通道是缺血条件下水进入中枢神经系统的主要途径,因此,这类患者可能会受益于抗水肿药物的治疗。

关于AER-271

AER-271是首创新药,用于治疗脑卒中患者的脑水肿(脑肿胀),目前已成功完成临床一期试验。

关于Aeromics

Aeromics是一家临床阶段的私有化制药公司,致力于从根本上解决因为水动态失衡而导致的疾病。

更多信息请访问:www.aeromics.com

关于先声药业

先声药业是中国领先的研发驱动型制药公司,拥有“转化医学与创新药物国家重点实验室”,聚焦神经、肿瘤、自身免疫等重大疾病领域,致力于让患者早日用上更好药物。凭借优异的商业化能力,其主要产品在中国保持领先的市场份额。先声药业秉持开放式创新的研发策略,与多家跨国药企成为战略合作伙伴,促进全球生命科学成果在中国的价值实现。

更多信息请访问:www.simcere.com

Aeromics and Simcere Announce Collaboration and License Agreement for AER-271 in Greater China

New Haven, Connecticut, USA, Nanjing, China, 5th November 2019 – Simcere Pharmaceutical Group andAeromics , Inc. Today announce collaboration and exclusive license agreement for AER-271, a clinical-stage anti-edema therapy, being developed for the treatmentof stroke and other indications, in Greater China (mainland China, Hong Kong, Macau and Taiwan). According to the agreement, Simcere will be responsible for the clinical development and commercialization of AER-271 in Greater China.

“We are delighted to be working with Simcere to develop AER-271 in China. Simcere’s leading position in the Greater China stroke market, their strengths in manufacturing and the collaborative nature of their team made for an ideal partner for Aeromics,” said Thomas Zindrick, Aeromics’ Executive Vice Chairman.

Dr. Pin Wang, CSO of Simcere stated on the collaboration, “Edema is a serious complication among many common illnesses of the central nervous system (CNS) such as brain injury and cerebrovascular diseases, with a huge unmet medical need. Aeromics has an excellent research team and expertise in the stroke area, while Simcere has extensive experience in the drug development and commercialization of CNS diseases. We are pleased to have the opportunity to collaborate with Aeromics and hope we will bring AER-271 to patients soon with our joint efforts. ” 

Dr. Peter Agre, Aeromics Board member, the 2003 Nobel Prize in Chemistry for discovery of the aquaporin water channels and commented, “By bringing together the complementary expertise of Aeromics and Simcere, I am very gratified we will together advance the development of a therapeutic for a significant unmet medical need, based on the initial insights into aquaporin biology.” 

Under terms of the collaboration, Aeromics will receive an up-front payment and additional payments contingent on certain development, regulatory, and commercial milestones, plus tiered royalties on net sales ranging from highsingle digit to double digit percentages. Simcere will be responsible for leading development and commercialization of AER-271 in Greater China and will receive a single-digit percentage royalty from the net sales of AER-271 in therest of the world. Detailed financial terms were not disclosed.

About Stroke

Every 20-30 seconds someone in China suffers from a stroke. Roughly 2,500,000 strokes are seen in China each year, many of which suffer life-threatening and severely disabling cerebral edema, or brain swelling, and may benefit from ananti-edema medication. Aquaporin-4 (AQP4) water channels are the primary routeof water movement into the central nervous system under conditions of ischemia.

About AER-271

AER-271 is a first-in-class, proprietary, intravenous (IV) prodrug thatdelivers AER-270, a potent inhibitor of AQP4 water channels for the treatment cerebral edema (brain swelling) in patients that have suffered ischemic strokes. AER-271 is an investigational drug that has successfully completed a Phase 1 study and is not yet approved by any regulatory agency.

About Aeromics

Aeromics is a privately held, clinical-stage pharmaceutical company dedicated to fundamentally changing the way various conditions resulting from the loss of water homeostasis are treated.

For more information about AER-271 and Aeromics, please visit: www.aeromics.com.

About Simcere

Simcere is a research and development-driven Chinese pharmaceutical company with a State Key Lab of Translational Medicine and Innovative Drug Development, committed to delivering high quality and effective therapies to patients. Simcere achieves this by focusing its efforts on therapeutic areas of neurology, oncology, immunology diseases etc. By leverage of its commercial capability, all top products of the company have a leading market share in China. Simcere continues to promote the advance of international scientific and medical breakthroughs through an open and collaborative R&D strategy, and extensive strategic partnerships with several multi-national companies.

For more information, please visit: 
www.simcere.com.

赞(0)
未经允许不得转载:药通社 » 先声药业与Aeromics宣布合作,在大中华区共同研发和商业化脑水肿治疗药物AER-271
分享到: 更多 (0)

评论 抢沙发

  • 昵称 (必填)
  • 邮箱 (必填)
  • 网址

药融圈药通社